Introduction
============

There has been steady improvement in the survival of breast cancer patients in recent decades; however, late development of brain metastases is an increasing problem in long-term survivors. In fact, breast cancer is the second most common origin of brain metastasis in cancer patients \[[@b1-crt-2016-303]\]. Intensive treatments, including surgery, radiosurgery, and conventional radiotherapy (RT), can substantially increase survival in some subgroups of patients with a limited number of brain metastases, controlled extracranial disease, and good performance status \[[@b2-crt-2016-303],[@b3-crt-2016-303]\].

Whole-brain RT (WBRT) following surgical resection of brain metastases has a well-established role in preventing intracranial failure \[[@b4-crt-2016-303],[@b5-crt-2016-303]\]. Because of concern about possible long-term neurocognitive sequelae, partial radiotherapy (PRT) to the tumor bed has been proposed as a substitute for WBRT \[[@b6-crt-2016-303],[@b7-crt-2016-303]\]. However, PRT after surgery is associated with increased risk of leptomeningeal carcinomatosis (LMC) or distant brain failure relative to WBRT \[[@b8-crt-2016-303],[@b9-crt-2016-303]\].

The risk of LMC should be carefully considered when applying PRT after surgery because of the theoretical possibility of cerebrospinal fluid (CSF) contamination with tumor cells during surgical resection of brain metastases. A few retrospective studies have compared postoperative WBRT and PRT \[[@b8-crt-2016-303],[@b9-crt-2016-303]\]. However, these studies included patients with any type of primary cancer, and none of these studies included breast cancer patients alone. Therefore, the present study was conducted to determine the incidence of LMC according to the extent of brain RT after surgical resection of brain metastases in breast cancer patients.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively reviewed the medical records of breast cancer patients with brain metastases who underwent surgical resection between March 2001 and March 2015 at the National Cancer Center of Korea (Goyang) or between November 2003 and March 2015 at the Severance Hospital of Korea (Seoul). After excluding patients who received RT before surgical resection of brain metastases, 51 patients were included in this study. Overall, 34 patients received postoperative RT, being WBRT in 24 patients and PRT to the tumor bed in 10 patients.

2. Radiotherapy
---------------

The postoperative treatment strategy; namely, whether or not to give RT and to what extent, was selected according to the physician's preference. A WBRT of 25 or 30 Gy in 10 fractions (fx) or 30 Gy in 12 fx (median 30 Gy/10 fx) was administered using a linear accelerator with conventional two opposing lateral fields. There was a difference in treatment strategy in terms of the boost to the tumor bed between the centers. A boost (dose range, 7.5 to 25 Gy; median, 15 Gy in 3-10 fx) after WBRT was routinely prescribed in one center, but not the other. PRT was applied to the resection cavity with a suitable margin using stereotactic or three-dimensional conformal techniques at various dose fractions: 36 Gy/6 fx (n=4), 45 Gy/15 fx (n=2), 45 Gy/10 fx (n=1), and 36 Gy/12 fx (n=1). In two patients who were treated with gamma knife radiosurgery, 16 Gy and 7.5 Gy were prescribed to the 50% isodose line in a single fraction, respectively.

3. Clinical factors
-------------------

In addition to the extent of brain RT, the following clinical variables were reviewed as potential prognostic factors for the recurrence of leptomeningeal disease: age at diagnosis of brain metastasis, systemic disease status (none/stable vs. progressive), biological subtype of primary tumor, Eastern Cooperative Oncology Group (ECOG) performance status, breast specific graded prognostic assessment score (Breast-GPA) \[[@b10-crt-2016-303]\], size and number of metastases, extent of resection (gross total resection vs. subtotal resection), hormone therapy, and systemic treatment. Systemic treatment included chemotherapy, targeted therapy, or both and was given after brain surgery and before the development of LMC or dural metastasis (DM) (LMCDM). Systemic treatment at any time after brain surgery was separately analyzed as a prognostic factor for overall survival (OS). Biological subtypes of primary tumors were classified as follows: estrogen receptor--positive and/or progesterone receptor--positive/human epidermal growth factor receptor (HER2)--negative, HER2-positive, and triple-negative according to the previous studies \[[@b11-crt-2016-303]\]. Continuous variables were dichotomized by their median values. We also analyzed the location of the tumor relative to CSF flow. The tumor was classified as adjacent to CSF flow if there was contact of the tumor's surface with the pia mater or ventricle wall \[[@b12-crt-2016-303]\].

4. Outcome evaluation
---------------------

The patients were followed-up with magnetic resonance imaging (MRI) at intervals of 3 months after surgery. The primary outcome was the development of LMCDM after treatment for brain metastases. LMC was diagnosed based on MRI and/or CSF cytology confirmation. The conservative definition of LMC (i.e., presence of malignant cells in CSF or typical leptomeningeal enhancement on MRI in the brain, spinal cord, or cauda equina) was used. DM was defined as a presence of multiple enhancing nodules on the dura mater on MRI ([Fig. 1](#f1-crt-2016-303){ref-type="fig"}). Both incidence of LMC and DM were analyzed together as a LMCDM.

Local recurrence (LR) was defined as the appearance of new enhancing lesions within the resection cavity. Distant brain recurrence (DBR) was defined as the presence of new metastatic nodules in distinct brain parenchyma outside the resection cavity.

Considering the emerging evidence of the importance of biological subtype and targeted therapy in breast cancer prognosis and treatment \[[@b11-crt-2016-303]\], subgroup analysis according to the HER2 status was conducted to evaluate the impact of targeted therapy on the development of LMCDM and OS.

5. Statistical analysis
-----------------------

Patient characteristics were compared among the three treatment groups using Fisher exact test for categorical variables and the Mann-Whitney U test or one-way analysis of variance for continuous variables, as appropriate. The Kaplan-Meier method was used to assess event-time distributions. The time to recurrence was calculated from the date of surgical resection to the date of MRI showing LR, DBR, or LMCDM. Otherwise, patients were censored at the time of their last MRI or the clinical visit when their neurologic signs were last evaluated. OS was calculated from the date of surgery to the date of death, or living patients were censored at the date of their last clinical visit. Log-rank tests were used to compare the event-time distributions among treatment groups. The Cox proportional hazard model was used in multivariate analysis to identify factors associated with LMCDM by calculating hazard ratio (HR) with 95% confidence intervals (CI). A stepwise backward linear regression was employed, and variables with p-values greater than 0.10 were removed from the model. The study was sufficiently powered (88%) with a one-sided type I error probability of 5% to detect a HR of 3.3 for 27 patients who did not received postoperative WBRT relative to 24 patients who did. The HR of 3.3 was based on previous studies in which the HRs for LMC were 2.44 and 5.67 in patients who underwent postoperative PRT compared with those who underwent WBRT \[[@b8-crt-2016-303],[@b9-crt-2016-303]\]. The review and analysis of patient data in this study were approved by the Institutional Review Boards of both institutions.

Results
=======

1. Patient, tumor, and treatment characteristics
------------------------------------------------

The patient, tumor, and treatment characteristics are summarized in [Table 1](#t1-crt-2016-303){ref-type="table"}. The median age was 48 years (range, 34 to 75 years) in all patients, and was higher in the no RT group (60 years) than the WBRT (46 years) and PRT (45 years) groups, although this difference was not statistically significant (p=0.805). A boost RT was applied to the tumor bed in 16/24 patients who received WBRT. Overall, 69% of patients had no or stable extracranial disease and 71% had one brain lesion. All patients in the PRT group had no or stable extracranial disease, but the prevalence of extracranial disease was not significantly different among the three groups. The median size of the metastatic brain lesion was 3.5 cm (range, 1.0 to 8.0 cm). Additionally, 80% of all patients had tumors adjacent to the CSF flow. Hormone therapy was applied in 6/19 patients (32%) with hormone receptor--positive primary tumors.

Systemic treatment was administered after surgical resection and before the development of LMCDM in 71% of patients in the WBRT group, compared with 60% and 41% of patients in the PRT and no RT group (p=0.265). In a subgroup of 31 patients with HER2-positive primary tumors, 12 patients were given targeted therapy. The regimens of systemic treatment after brain surgery and before the development of LMCDM are listed in [S1 Table](#SD1-crt-2016-303){ref-type="supplementary-material"}. The three most commonly used regimens were capecitabine/lapatinib (37%), gemcitabine/cisplatin (33%), and capecitabine (30%).

2. Intracranial recurrence rate and pattern of failure
------------------------------------------------------

During the follow-up period, no intracranial recurrence was noted in 12 of the 24 patients in the WBRT group, two out of 10 in the PRT group, and seven out of 17 in the no RT group ([Fig. 2](#f2-crt-2016-303){ref-type="fig"}). LR and LMCDM were the major patterns of failure rather than DBR. Eight out of 17 patients (47%) in the no RT group developed LR, as did two out of 10 patients (20%) in the PRT group and five out of 24 patients (21%) in the WBRT group. LMCDM was less common in the WBRT group (25%, 6/24 patients) than in the no RT (47%, 8/17 patients) or PRT groups (80%, 8/10 patients). Patterns of failures according to the treatment groups and dose-fractionation of RT are listed in [S2 Table](#SD2-crt-2016-303){ref-type="supplementary-material"}.

3. Leptomeningeal carcinomatosis or dural metastasis
----------------------------------------------------

At a median follow-up of 12.4 months (range, 2.3 to 83.6 months), LMCDM was detected in 22 out of 51 patients (43%) after surgery. The median time to the diagnosis of LMCDM after surgery was 8.6 months (range, 4.8 to 51.2 months). The 18-month LMCDM-free survival (LMCDM-FS) rate was higher in the WBRT group (77.5%) than in the PRT group (30.0%, p=0.021) and no RT group (13.6%, p=0.007) ([Fig. 3A](#f3-crt-2016-303){ref-type="fig"}). There was no difference in 18-month LMCDM-FS between the PRT and no RT groups (p=0.449). When patients were divided into two groups according to whether they received WBRT or not, the LMCDM-FS was significantly better in the WBRT group than in the no WBRT group (77.5% vs. 22.6%, p=0.004) ([Fig. 3B](#f3-crt-2016-303){ref-type="fig"}).

[Table 2](#t2-crt-2016-303){ref-type="table"} shows the results of univariate analyses aimed at identifying which factors were potentially associated with the incidence of LMCDM. Tumors adjacent to the CSF flow were associated with increased risk of LMCDM. Postoperative WBRT and systemic treatment decreased the incidence of LMCDM. Tumor size, extent of resection, and biological subtype of the primary tumor were not associated with LMCDM upon univariate analyses. In the WBRT group, there were no differences in the incidence of LMCDM according to the dose-fractionation scheme of the WBRT. Multivariate analysis showed that WBRT and systemic treatment were significantly associated with reduced incidence of LMCDM. The HR relative to WBRT was 5.2 (95% CI, 1.9 to 14.8; p=0.009) for PRT and 2.7 (95% CI, 0.9 to 7.9; p=0.122) for no RT.

4. LR and OS
------------

The 18-month LR-free survival was 83.6%, 75.0%, and 14.1% in the WBRT, PRT, and no RT groups, respectively (p=0.002). The LR-free survival was significantly lower in the no RT group than in the other groups ([Fig. 4](#f4-crt-2016-303){ref-type="fig"}).

The median OS in all patients was 28.7 months. The median OS was 24.0 months in the WBRT group and 37.7 months in the PRT group, while it was 11.6 months in the no RT group. However, the OS did not differ significantly among the three groups (p=0.255) ([Fig. 5](#f5-crt-2016-303){ref-type="fig"}). The OS values did not differ among biological subtypes of the primary tumor upon univariate analysis (p=0.562). The median OS was longer in patients with no or stable extracranial disease than those with progressive disease (median, 32.6 months vs. 11.6 months; p=0.067), although the difference was not statistically significant. Systemic treatment was also associated with a longer median survival time (yes, 32.6 months vs. no, 24.0 months; p=0.019).

5. Subgroup analysis according to HER2 status
---------------------------------------------

In the 31 patients with HER2-positive primary tumors, systemic treatment including targeted therapy was associated with improved LMDCM-FS when compared with no systemic treatment (p=0.002). In the 20 patients with HER2-negative primary tumor, systemic treatment decreased the incidence of LMCDM (p \< 0.001) ([S3 Fig.](#SD3-crt-2016-303){ref-type="supplementary-material"}).

Systemic treatment including targeted therapy was also associated with better OS than no systemic treatment in the HER2-positive subgroup of patients (p=0.047). In the HER2-negative subgroup of patients, systemic treatment did not improve median OS (p=0.159) ([S4 Fig.](#SD4-crt-2016-303){ref-type="supplementary-material"}).

Discussion
==========

This study was conducted to assess the effects of postoperative WBRT on LMCDM and to identify the risk factors associated with LMCDM in patients who underwent surgical resection of brain metastases from breast cancer. LMCDM occurred in 22/51 patients (43%) and was the most common pattern of disease recurrence after surgical resection in this study. Patients who received WBRT had less LMCDM than those who received PRT. These results are consistent with those of previous retrospective studies that compared the outcomes of WBRT and PRT in postoperative settings. Patel et al. \[[@b8-crt-2016-303]\] reported 18-month LMC rates of 13% with WBRT and 31% with stereotactic radiosurgery (SRS) (p=0.045). Hsieh et al. \[[@b9-crt-2016-303]\] also reported a lower rate of LMC with WBRT (p=0.02).

Our study also demonstrated an association between the presence of a tumor adjacent to CSF flow and increased risk of LMCDM. Several other studies found an association between tumor location and LMC. Some studies have reported that the rate of LMC after surgical resection was higher for posterior fossa tumors than for supratentorial tumor \[[@b13-crt-2016-303],[@b14-crt-2016-303]\]. Theoretically, there is a greater chance of CSF exposure during resection of posterior fossa tumors. Ahn et al. \[[@b12-crt-2016-303]\] classified tumor location relative to CSF flow. Their study showed an increased risk of LMCDM in patients with a tumor adjacent to the CSF flow (HR, 9.00; p \< 0.01), consistent with our results. Although this association was not significant in our multivariate analysis, we assume that the patients with tumors adjacent to CSF flow could be at a high risk of LMCDM and that postoperative WBRT needs to be considered.

Concern about the risk of neurotoxicity from WBRT is the main reason postoperative local RT is often applied instead of WBRT in many clinical situations \[[@b6-crt-2016-303],[@b7-crt-2016-303],[@b15-crt-2016-303],[@b16-crt-2016-303]\]. However, intracranial disease progression is another important cause of neurocognitive deterioration \[[@b17-crt-2016-303]\]. Occurrence of LMCDM is associated with significant morbidity, and intensive treatment of LMCDM can markedly compromise patient quality of life. Thus, it is particularly important to identify patients at higher risk of LMCDM and prevent the development of LMCDM, especially among those in whom long-term survival is expected. In the WBRT group, various dose-fractionation schemes (30 Gy/10 fx, 30 Gy/12 fx, or 25 Gy/10 fx) were used, all of which resulted in favorable outcomes. In patients with small cell lung cancer, prophylactic cranial irradiation of 25 Gy in 10 fx has been a standard regimen because increased risk of chronic neurotoxicity at higher doses had been reported \[[@b18-crt-2016-303]\]. Taken together, these results indicate that postoperative WBRT 25 Gy in 10 fx followed by local boost can be considered after surgical resection of brain metastases to minimize neurotoxicity while achieving an acceptable tumor control.

The incidence of LMCDM was higher in our study than the incidence of LMC in previous reports, which included patients with brain metastases from any primary tumor \[[@b19-crt-2016-303],[@b20-crt-2016-303]\]. The broader criterion for the diagnosis of LMCDM used in our study may explain the higher incidence. Twenty two patients developed LMCDM, eight of whom were diagnosed with dural metastasis. Like the patients with LMC, those with dural metastasis eventually require salvage therapy, including WBRT and intrathecal chemotherapy, and are at greater risk of toxicity because of these aggressive treatments. Thus, multiple enhancing dural nodules were also analyzed as LMCDM rather than DBR. Because the incidence of both LMC and dural metastasis can be affected by the extent of postoperative RT, we expected this broad criterion of LMCDM would be useful to identify patients in whom WBRT needs to be considered.

The lower incidence of LMCDM in the WBRT group was not associated with prolonged survival. The median survival was longer in PRT groups (37.7 months) than those in the no RT (11.6 months) or WBRT group (24.0 months), but this difference was not statistically significant. We assume that these results were caused by differences in baseline characteristics among groups. In the PRT group, there were more patients with a Breast-GPA score of 3.5-4.0, who were expected to have better prognosis than others, although this difference was not statistically significant. There was also a possibility that physicians had selected patients with good prognostic factors including Breast-GPA and were expected to live longer to receive PRT rather than WBRT to avoid neurotoxicity. The longer survival time in the PRT group suggests that patients might have had a greater chance to develop LMCDM because they lived longer than others. This possibility cannot be thoroughly investigated based on the present study. However, considering that the median time to develop LMCDM was only 8.6 months, the median survival time of the no RT or WBRT group was not too short to underestimate the LMCDM.

In addition to WBRT and tumor location, several other factors were reportedly associated with the development of LMC in previous studies. For example, primary tumor histology, size of resected lesion, piecemeal resection, and previous intracranial recurrence were associated with the incidence of LMC following surgical resection of brain metastases \[[@b12-crt-2016-303],[@b20-crt-2016-303]-[@b24-crt-2016-303]\]. The number of brain metastasis and location of systemic disease progression were prognostic factors for LMC in patients who underwent upfront SRS for brain metastases \[[@b19-crt-2016-303],[@b25-crt-2016-303],[@b26-crt-2016-303]\]. In the current study, we found that systemic treatment after resection of brain metastases was significantly associated with reduced risk of LMCDM, with a HR of 0.1 compared to the patients who did not receive systemic treatment (p \< 0.001). These findings are contrary to the widely accepted concept that systemic treatment is less effective in patients with brain metastasis because of the blood-brain barrier (BBB).

However, there is evidence that some targeted agents can cross the BBB \[[@b27-crt-2016-303]\]. Lapatinib is known to cross the BBB because of its very low molecular weight (581 Da), and several studies evaluating the effects of lapatinib in patients with metastatic brain tumor from the breast are ongoing (NCT-01622868 and NCT01218529). This can explain the improved LMCDM-FS in patients with HER2-positive primary tumor who underwent targeted therapies in this study. Among 12 patients who received targeted therapy, 11 were treated with lapatinib.

Patients with HER2-negative primary tumor also had an improved LMCDM-FS with chemotherapeutic agents upon subgroup analysis. Because all patients in this study underwent surgical resection of brain metastasis, the systemic agents might be able to cross the disrupted BBB, and hence eliminate the microscopically seeded tumor cells in the CSF. However, the heterogeneity of the regimens and diverse clinical situations make it difficult to determine the impact of systemic treatment on the development of LMCDM in the current study.

The strength of our study lies in the homogeneous study population. All of the patients underwent surgical resection of brain metastases from breast cancer. It should be noted that most of the previous studies included mixed populations of patients with metastases from a variety of primary solid tumor types, and more than half of the study populations in prior studies had primary lung cancer. To date, very few studies have determined the incidence of LMC after resection of brain metastases in breast cancer patients. Brain metastases of breast cancer should be separated from those of other primary tumors because of the much longer survival time. De Ieso et al. \[[@b28-crt-2016-303]\] reported that intensive treatment, including surgery and/or stereotactic RT, of brain metastases can result in long-term survival of more than 2 years in breast cancer patients with a limited number of brain metastases. Thus, both the effective disease control and preservation of quality of life should be pursued in these patients, and determining the proper extent of RT after surgical resection of brain metastasis is of particularly great importance.

There are limitations inherent to retrospective studies. The small number of patients and the baseline imbalance in patient characteristics among treatment groups might have biased the apparent effects of the WBRT. The effects of several factors known to increase the risk of LMC in previous studies, including the location and size of the tumor or the number of lesions, were not fully demonstrated in this study.

Given the inherent bias in retrospective analyses, a large prospective study of breast cancer patients with brain metastases is needed to precisely define high-risk patients who need to receive WBRT after surgery.

Conclusion
==========

WBRT improved the LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients. Patients with tumors adjacent to the CSF flow are at higher risk of LMCDM, and these patients might need to be treated with postoperative WBRT. The effects of systemic treatment on LMCDM needs to be evaluated in further studies.
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###### S1 Table.

Systemic treatment regimens after brain surgery and before the development of leptomeningeal carcinomatosis or dural metastasis

###### S2 Table.

Pattern of failures according to the treatment groups and dose-fractionation of radiation

###### S3 Fig.

Leptomeningeal or dural metastasis--free survival (LMCDM-FS) according to the systemic treatments in human epidermal growth factor receptor 2 (HER2)--positive (n=31) (A) and HER2-negative (n=20) (B) subgroups of patients. In patients with HER2-positive primary tumor, targeted therapy (Targeted Tx) with or without chemotherapy (CTx), CTx, and no systemic treatment (Tx) were compared. In patients with HER2-negative primary tumor, CTx was compared with no systemic Tx.

###### S4 Fig.

Overall survival according to the systemic treatments in human epidermal growth factor receptor 2 (HER2)--positive (n=31) (A) and HER2-negative (n=20) (B) subgroups of patients. In patients with HER2-positive primary tumor, targeted therapy (Targeted Tx) with or without chemotherapy (CTx), CTx, and no systemic treatment (Tx) were compared. In patients with HER2-negative primary tumor, CTx was compared with no systemic Tx.

![(A-D) Gadolinum enhanced T1 weighted magnetic resonance imaging (MRI) image of a patient who developed multiple enhancing dural nodules 6 months after surgical resection for brain metastasis and postoperative partial radiotherapy to the tumor bed. Dural metastasis was defined as a presence of such multiple enhancing nodules on the dura mater on MRI.](crt-2016-303f1){#f1-crt-2016-303}

![Intracranial recurrence rate and pattern of failures in three treatment groups: no radiotherapy (RT) group (n=17), partial RT (PRT) group (n=10), and whole brain radiotherapy (WBRT) group (n=24). LR, local recurrence; DBR, distant brain recurrence; LMCDM, leptomeningeal carcinomatosis or dural metastasis.](crt-2016-303f2){#f2-crt-2016-303}

![Leptomeningeal carcinomatosis or dural metastasis--free survival (LMCDM-free survival) comparing three treatment groups (whole brain radiotherapy \[WBRT\] group \[n=24\], partial radiotherapy \[PRT\] group \[n=10\], and no radiotherapy \[RT\] group \[n=17\]) (A) and comparing two groups (WBRT \[n=24\] or not \[n=27\]) (B).](crt-2016-303f3){#f3-crt-2016-303}

![Local recurrence--free survival for whole brain radiotherapy (WBRT) group (n=24), partial radiotherapy (PRT) group (n=10), and no radiotherapy (RT) group (n=17).](crt-2016-303f4){#f4-crt-2016-303}

![Overall survival for whole brain radiotherapy (WBRT) group (n=24), partial radiotherapy (PRT) group (n=10), and no radiotherapy (RT) group (n=17).](crt-2016-303f5){#f5-crt-2016-303}

###### 

Patient, tumor, and treatment characteristics

  Characteristic                                                                          All (n=51)         WBRT (n=24)        PRT (n=10)        No RT (n=17)     p-value
  --------------------------------------------------------------------------------------- ------------------ ------------------ ----------------- ---------------- ---------------------------------------------------------
  **Age, median (range, yr)**                                                             48 (34-75)         46 (34-68)         45 (34-68)        60 (34-75)       0.805^[a)](#tfn1-crt-2016-303){ref-type="table-fn"}^
  **Duration between brain metastasis and breast cancer diagnosis, median (range, mo)**   35.1 (5.0-148.0)   29.9 (7.8-148.0)   32.4 (9.8-67.5)   41 (5.0-115.9)   0.835^[a)](#tfn1-crt-2016-303){ref-type="table-fn"}^
  **Extracranial disease status**                                                                                                                                  
   None or stable                                                                         35 (69)            15 (63)            10 (100)          10 (59)          0.056^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   Progressive                                                                            16 (31)            9 (38)             0                 7 (41)           
  **Biological subtype of primary tumor**                                                                                                                          
   ER+ and/or PR+, HER2−                                                                  7 (14)             3 (13)             0                 4 (24)           0.556^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   HER2-positive                                                                          31 (60)            14 (58)            7 (70)            10 (59)          
   Triple-negative                                                                        13 (26)            7 (29)             3 (30)            3 (18)           
  **ECOG performance status**                                                                                                                                      
   0-1                                                                                    47 (92)            22 (92)            9 (90)            16 (94)          \> 0.990^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   2                                                                                      4 (8)              2 (8)              1 (10)            1 (6)            
  **Breast-GPA**                                                                                                                                                   
   3.5-4.0                                                                                13 (26)            5 (21)             5 (50)            3 (18)           0.314^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   2.5-3.0                                                                                21 (41)            9 (38)             2 (20)            10 (56)          
   1.5-2.0                                                                                15 (29)            8 (33)             3 (30)            4 (24)           
   0.5-1.0                                                                                2 (4)              2 (8)              0                 0                
  **No. of brain metastases**                                                                                                                                      
   1                                                                                      36 (71)            14 (58)            7 (70)            15 (88)          0.117^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   2-3                                                                                    15 (29)            10 (42)            3 (30)            2 (12)           
  **Size, median (range, cm)**                                                            3.5 (1.0-8.0)      3.6 (1.6-6.0)      3.5 (2.0-6.0)     2.9 (1.0-8.0)    0.518^[a)](#tfn1-crt-2016-303){ref-type="table-fn"}^
  **Adjacent to CSF flow^[c)](#tfn3-crt-2016-303){ref-type="table-fn"}^**                                                                                          
   No                                                                                     10 (20)            4 (17)             1 (10)            5 (29)           0.479^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   Yes                                                                                    40 (80)            19 (83)            9 (90)            12 (71)          
  **Extent of resection**                                                                                                                                          
   GTR                                                                                    40 (78)            18 (75)            7 (70)            15 (88)          0.447^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   STR                                                                                    11 (22)            6 (25)             3 (30)            2 (12)           
  **HRT after brain surgery**                                                                                                                                      
   Yes                                                                                    6 (12)             3 (6)              2 (20)            1 (6)            0.549^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   No                                                                                     45 (88)            21 (88)            8 (80)            16 (94)          
  **Systemic treatment after brain surgery and before the development of LMCDM**                                                                                   
   No                                                                                     21 (42)            7 (29)             4 (40)            10 (59)          0.265^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   Targeted Tx±CTx                                                                        13 (26)            6 (25)             4 (40)            3 (18)           
   CTx                                                                                    17 (33)            11 (46)            2 (20)            4 (24)           
  **Systemic treatment after brain surgery (at any time)**                                                                                                         
   No                                                                                     16 (31)            7 (29)             1 (10)            8 (47)           0.291^[b)](#tfn2-crt-2016-303){ref-type="table-fn"}^
   CTx with targeted Tx                                                                   15 (29)            6 (25)             5 (50)            4 (24)           
   CTx without targeted Tx                                                                20 (39)            11 (46)            4 (40)            5 (29)           

Values are presented as number (%). WBRT, whole brain radiotherapy; PRT, partial radiotherapy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ECOG, Eastern Cooperative Oncology Group; Breast-GPA, breast specific graded prognostic assessment score; CSF, cerebrospinal fluid; GTR, gross total resection; STR, subtotal resection; HRT, hormone therapy; Tx, therapy; CTx, chemotherapy.

One-way ANOVA,

Fisher exact test,

n=50 (WBRT, 23; PRT, 10; no RT, 17).

###### 

Univariate and multivariate analysis for lLMCDM-FS

  Characteristic                                                                   No. of patients   Univariate analysis   Multivariate analysis                    
  -------------------------------------------------------------------------------- ----------------- --------------------- ----------------------- ----- ---------- ----------
  **Extracranial disease status**                                                                                                                                   
   None or stable                                                                  35                42.1                  0.113                                    
   Progressive                                                                     16                64.8                                                           
  **Biological subtype of primary tumor**                                                                                                                           
   ER+ and/or PR+, HER2−                                                           7                 53.6                  0.882                                    
   HER2-positive                                                                   19                44.1                                                           
   Triple negative                                                                 13                58.3                                                           
  **No. of brain metastases**                                                                                                                                       
   1                                                                               36                45.1                  0.191                                    
   2-3                                                                             15                60.0                                                           
  **Size (cm)**                                                                                                                                                     
   \< 3.5                                                                          23                51.3                  0.906                                    
   ≥ 3.5                                                                           27                41.1                                                           
  **Adjacent to CSF flow^[d)](#tfn7-crt-2016-303){ref-type="table-fn"}^**                                                                                           
   No                                                                              10                80.0                  0.050                   1.0   \-         \-
   Yes                                                                             40                40.3                                          2.3   0.4-13.5   0.456
  **Extent of resection**                                                                                                                                           
   GTR                                                                             40                42.6                  0.120                                    
   STR                                                                             11                71.4                                                           
  **Systemic treatment after brain surgery and before the development of LMCDM**                                                                                    
   No                                                                              21                8.0                   \< 0.001                1.0   \-         \-
   Targeted Tx±CTx                                                                 13                69.8                                          0.1   0.0-0.3    \< 0.001
   CTx                                                                             17                67.5                                          0.1   0.0-0.3    \< 0.001
  **Postoperative RT**                                                                                                                                              
   WBRT                                                                            24                77.5                  0.013                   1.0   \-         \-
   PRT                                                                             10                30.0                                          5.2   1.9-14.8   0.009
   No RT                                                                           17                13.6                                          2.7   0.9-7.9    0.122
  **Postoperative WBRT**                                                                                                                                            
   Yes                                                                             24                77.5                  0.004                                    
   No                                                                              27                22.6                                                           
  **WBRT dose−fractionation**                                                                                                                                       
   25 Gy/10 fx                                                                     9                 65.6                  0.945                                    
   30 Gy/12 fx                                                                     6                 100.0                                                          
   30 Gy/10 fx                                                                     9                 71.4                                                           

LMCDM-FS, leptomeningeal carcinomatosis or dural metastasis--free survival; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CSF, cerebrospinal fluid; GTR, gross total resection; STR, subtotal resection; Tx, therapy; CTx, chemotherapy; RT, radiotherapy; WBRT, whole brain radiotherapy; PRT, partial radiotherapy; fx, fractions.

Log-rank test,

Hazard ratio refers to the risk of leptomeningeal carcinomatosis or dural metastasis per unit time,

Cox proportional hazard model (backward likelihood ratio),

n=50 (WBRT, 23; PRT, 10; no RT, 17).

[^1]: Boram Ha and Seung Yeun Chung contributed equally to this work.
